ORPHA:790
Retinoblastoma
Publications
71,348
Trials
88
Interventional, condition-specific
Researchers
1,263
Distinct authors in sample
Gene link
RB1
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare eye tumor disease representing the most common intraocular malignancy in children. It is a life threatening neoplasia but is potentially curable and it can be or non , unilateral or bilateral.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0008380
- MeSH:D012175
- UMLS:C0035335
- NCIT:C7541
Additional Mondo synonyms (3)
RB · retinoblastoma · retinoblastoma, malignant
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — RB1
- LiteraturePresent
71,348 matched papers (31,435 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
88 matched on ClinicalTrials.gov (9 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (RB1).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
71,348
71,348 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
71,348 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
31,435 in the last 10 years · low confidence
Phrase hits: 71,348 · MeSH hits: 1,588
Who's working on it?
1,263
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Liu Y7 papers · 2026
Department of Biochemistry, Stanford University School of Medicine, Stanford, CA, USA.
Papers in Europe PMC - 02Zhang Y7 papers · 2026
Department of Biochemistry, Stanford University School of Medicine, Stanford, CA, USA.
Papers in Europe PMC - 03Chen Y5 papers · 2026
Section of Pacing and Electrophysiology, Division of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Papers in Europe PMC - 04Munier FL5 papers · 2026
Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, Lausanne, Switzerland.
Papers in Europe PMC - 05Zhang J5 papers · 2026
Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.
Papers in Europe PMC - 06Zhang X5 papers · 2026
Department of Ophthalmology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Papers in Europe PMC - 07Zhao J5 papers · 2026
Department of Ophthalmology, Pediatric Oncology Center, Beijing Children's Hospital, Beijing, China.
Papers in Europe PMC - 08Li X4 papers · 2026
State Key Laboratory of Pharmaceutical Biotechnology, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Medical School, Nanjing University, Nanjing, China.
Papers in Europe PMC - 09Liu H4 papers · 2026
Department of Ophthalmology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Papers in Europe PMC - 10Stathopoulos C4 papers · 2026
Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, Lausanne, Switzerland.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
88
interventional trials for this specific condition
88 interventional trials matched this specific condition name; 9 currently recruiting in our sample.
Data as of 27 July 2026
88 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 98.2th percentile).
low confidence · 98.2th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
88 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT04799002·RECRUITING·Topotecan and Melphalan for Retinoblastoma
Conditions: Retinoblastoma · Chemotherapy Effect·Matched via name + MeSH
- NCT04903678·RECRUITING·Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma
Conditions: Retinoblastoma, Extraocular·Matched via name + MeSH
- NCT06424301·RECRUITING·Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma
Conditions: Retinoblastoma · Refractory·Matched via name + MeSH
- NCT05504291·RECRUITING·A Study to Give Treatment Inside the Eye to Treat Retinoblastoma
Conditions: Bilateral Retinoblastoma · Childhood Intraocular Retinoblastoma · Group D Retinoblastoma · Stage I Retinoblastoma·Matched via name + MeSH
- NCT04681417·RECRUITING·Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome
Conditions: Retinoblastoma·Matched via name + MeSH
- NCT05080010·RECRUITING·Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma
Conditions: Retinoblastoma·Matched via name + MeSH
- NCT06972602·RECRUITING·High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed
Conditions: Retinoblastoma · Retinoblastoma, Recurrent·Matched via name + MeSH
- NCT05650749·RECRUITING·GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
Conditions: Refractory Neuroblastoma · Relapsed Neuroblastoma · High-risk Neuroblastoma · Retinoblastoma·Matched via name + MeSH
- NCT06679634·RECRUITING·Retinoblastoma Phase II Expanded Access Clinical Trial
Conditions: Retinoblastoma·Matched via name + MeSH
Observational and natural-history studies
37 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT04425434·RECRUITING·Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma
Conditions: Retinoblastoma·Matched via name + MeSH
- NCT03050268·RECRUITING·Familial Investigations of Childhood Cancer Predisposition
Conditions: Acute Leukemia · Adenomatous Polyposis · Adrenocortical Carcinoma · AML·Matched via name + MeSH
- NCT01109394·RECRUITING·Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
Conditions: Sarcoma · Endocrine Tumors · Neuroblastoma · Retinoblastoma·Matched via name + MeSH
- NCT03662776·ENROLLING BY INVITATION·Effect of Treatment Modality on Psychosocial Functioning of Survivors of Unilateral Retinoblastoma
Conditions: Survivors of Unilateral Retinoblastoma·Matched via name + MeSH
- NCT04959097·RECRUITING·Retinoblastoma Patient Clinical Database and Tissue Repository
Conditions: Retinoblastoma · Retinoblastoma Bilateral · Retinoblastoma Unilateral·Matched via name + MeSH
- NCT06367530·RECRUITING·Trilateral Retinoblastoma: Incidence and Outcomes
Conditions: Trilateral Retinoblastoma · Retinoblastoma·Matched via name + MeSH
- NCT07530458·NOT YET RECRUITING·Retinoblastoma Consolidation in Egyptians
Conditions: Retinoblastoma·Matched via name + MeSH
- NCT03546387·RECRUITING·Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients
Conditions: Pediatric Retinoblastoma · Retinoblastoma·Matched via name + MeSH
- NCT06227962·ENROLLING BY INVITATION·Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors
Conditions: Retinoblastoma · Neurocognitive Dysfunction · Health-Related Behavior·Matched via name + MeSH
- NCT03267459·RECRUITING·Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma?
Conditions: Retinoblastoma·Matched via name + MeSH
- NCT03932786·RECRUITING·Studying Health Outcomes After Treatment in Patients With Retinoblastoma
Conditions: Retinoblastoma · Cancer Survivor · Biological Sibling · Intraocular Retinoblastoma·Matched via name + MeSH
- NCT06725173·RECRUITING·Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.
Conditions: Retinoblastoma Bilateral · Retinoblastoma Unilateral · Retinoblastoma, Extraocular · Retinoblastoma, Recurrent·Matched via name + MeSH
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Retinoblastoma" OR "retinoblastoma, malignant"
MeSH descriptor terms unioned into the query: Retinoblastoma
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Retinoblastoma" OR "retinoblastoma, malignant"
Interventional trials matched via: both (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 88 interventional · 37 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: RB
Confidence reasoning
- Preferred label is short or not clearly distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (71348) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-26T15:21:50.392Z
